Cargando…

Emergence of SARS‐CoV‐2 spike protein at the vaccination site

BACKGROUND: The anti‐coronavirus disease 2019 (COVID‐19) vaccines are of paramount importance in the fight against the COVID‐19 pandemic. Both viral vector‐ and nucleic acid‐based vaccines are known to effectively induce protection against the severe acute respiratory syndrome coronavirus 2 (SARS‐Co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beck, Annika, Dietenberger, Hanna, Kunz, Sebastian N., Mellert, Kevin, Möller, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052447/ https://www.ncbi.nlm.nih.gov/pubmed/36988249 http://dx.doi.org/10.1002/iid3.827

Ejemplares similares

SARS-CoV-2 variants – Evolution, spike protein, and vaccines
por: Chen, Kai-Wei K., et al.
Publicado: (2022)

The Emergence of the Spike Furin Cleavage Site in SARS-CoV-2
por: Chan, Yujia Alina, et al.
Publicado: (2021)

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
por: Hoffmann, Markus, et al.
Publicado: (2020)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

Sensitive on-site detection of SARS-CoV-2 by ID NOW COVID-19
por: Krause, Eva, et al.
Publicado: (2021)

Differences by region of birth in SARS-CoV-2 vaccine coverage and positive SARS-CoV-2 test among 400 000 healthcare workers and the general population in Sweden
por: Ljung, Rickard, et al.
Publicado: (2022)

SARS‐CoV‐2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID‐19 vaccination
por: Castruita, Jose Alfredo Samaniego, et al.
Publicado: (2023)

LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein
por: Shilts, Jarrod, et al.
Publicado: (2023)

Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2
por: Koyama, Takahiko, et al.
Publicado: (2022)

Human post‐infection serological response to the spike and nucleocapsid proteins of SARS‐CoV‐2
por: Xiao, Cheng, et al.
Publicado: (2020)

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
por: Weissman, Drew, et al.
Publicado: (2021)

Site-specific glycan analysis of the SARS-CoV-2 spike
por: Watanabe, Yasunori, et al.
Publicado: (2020)

SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
por: Velusamy, Palaniyandi, et al.
Publicado: (2021)

Laboratory biosafety emergency management for SARS-CoV-2
por: Lin, Kaili, et al.
Publicado: (2020)

Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding
por: Scheiblhofer, Sandra, et al.
Publicado: (2021)

The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET
por: Liu, Chuang, et al.
Publicado: (2020)

Penta-peptide ATN-161 based neutralization mechanism of SARS-CoV-2 spike protein
por: Rabbani, Gulam, et al.
Publicado: (2021)

Immunity evasion: consequence of the N501Y mutation of the SARS-CoV-2 spike glycoprotein
por: Uzoeto, Henrietta Onyinye, et al.
Publicado: (2022)

SARS-CoV-2 recombinant spike protein induces cell apoptosis in rat taste buds
por: Yamamoto, Toru, et al.
Publicado: (2023)

Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
por: Javanmardi, Kamyab, et al.
Publicado: (2022)

SARS-CoV-2 spike and its adaptable furin cleavage site
por: Whittaker, Gary R
Publicado: (2021)

Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation
por: Allen, Joel D., et al.
Publicado: (2021)

Coordinated evolution at amino acid sites of SARS-CoV-2 spike
por: Neverov, Alexey Dmitrievich, et al.
Publicado: (2023)

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2
por: Zheng, Zhiqiang, et al.
Publicado: (2020)

SARS‐CoV‐2 viral spike G614 mutation exhibits higher case fatality rate
por: Becerra‐Flores, Manuel, et al.
Publicado: (2020)

Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
por: Vankadari, Naveen
Publicado: (2020)

The polybasic insert, the RBD of the SARS-CoV-2 spike protein, and the feline coronavirus – evolved or yet to evolve
por: Budhraja, Anshul, et al.
Publicado: (2021)

Exploration of antigenic determinants in spike glycoprotein of SARS-CoV2 and identification of five salient potential epitopes
por: Agrawal, Aditya, et al.
Publicado: (2021)

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
por: Motozono, Chihiro, et al.
Publicado: (2021)

Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants
por: Pawłowski, Piotr H
Publicado: (2021)

Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery
por: Mohebbi, Alireza, et al.
Publicado: (2021)

Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations
por: Solanki, Kundan, et al.
Publicado: (2022)

Cervids ACE2 Residues that Bind the Spike Protein can Provide Susceptibility to SARS-CoV-2
por: Lopes, Luciano Rodrigo
Publicado: (2023)

Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses
por: Joseph, Jeswin, et al.
Publicado: (2021)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
por: Abdelghany, T.M., et al.
Publicado: (2021)

Shifts in global bat diversity suggest a possible role of climate change in the emergence of SARS-CoV-1 and SARS-CoV-2
por: Beyer, Robert M., et al.
Publicado: (2021)

SARS-CoV-2 infection in fully vaccinated healthcare workers
por: Hernández Porto, Miriam, et al.
Publicado: (2022)

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia
por: Liu, Yumei, et al.
Publicado: (2022)

COVID-19 vaccines and decreased transmission of SARS-CoV-2
por: Vitiello, A., et al.
Publicado: (2021)

Humoral and adaptive immune responses to the SARS-CoV-2 vaccine
por: Rizzo, Roberta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e1dlsl3vsfb8g7nihjntlaa0kq